Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Thalidomide

View Patient Information
A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:alpha-phthalimidoglutarimide
N-phthaloylglutamimide
N-phthalylglutamic acid imide
US brand name:Thalomid
Foreign brand name:Contergan
Distaval
Kevadon
Neurosedyn
Pantosediv
Sedoval K-17
Sedoval K17
Softenon
Talimol
Chemical structure:2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
2,6-dioxo-3-phthalimidopiperidine
3-phthalimidoglutarimide
N-(2,6-dioxo-3-piperidyl)phthalimide
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search